GUGLIELMELLI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.189
EU - Europa 19.282
AS - Asia 11.224
SA - Sud America 1.732
Continente sconosciuto - Info sul continente non disponibili 633
AF - Africa 327
OC - Oceania 189
AN - Antartide 1
Totale 58.577
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.698
PL - Polonia 6.093
RU - Federazione Russa 4.834
IT - Italia 3.487
SG - Singapore 3.095
CN - Cina 2.878
HK - Hong Kong 1.659
BR - Brasile 1.367
VN - Vietnam 1.169
IE - Irlanda 1.067
KR - Corea 1.012
SE - Svezia 843
FR - Francia 657
DE - Germania 549
FI - Finlandia 517
GB - Regno Unito 366
IN - India 331
CA - Canada 321
CH - Svizzera 276
BD - Bangladesh 224
AU - Australia 185
UA - Ucraina 170
ID - Indonesia 168
AR - Argentina 155
NL - Olanda 126
JP - Giappone 115
JO - Giordania 113
ES - Italia 100
TR - Turchia 80
CI - Costa d'Avorio 72
MX - Messico 72
IQ - Iraq 64
EC - Ecuador 56
ZA - Sudafrica 54
NG - Nigeria 49
PK - Pakistan 40
AT - Austria 37
CO - Colombia 34
MA - Marocco 32
CL - Cile 31
TW - Taiwan 30
BE - Belgio 27
PY - Paraguay 26
SA - Arabia Saudita 25
UZ - Uzbekistan 24
AE - Emirati Arabi Uniti 23
PH - Filippine 23
VE - Venezuela 23
MY - Malesia 21
KE - Kenya 19
DZ - Algeria 18
JM - Giamaica 18
NP - Nepal 18
CZ - Repubblica Ceca 17
TN - Tunisia 17
GR - Grecia 15
UY - Uruguay 15
BJ - Benin 14
CR - Costa Rica 14
EG - Egitto 14
PE - Perù 14
AL - Albania 13
RO - Romania 12
AZ - Azerbaigian 11
IL - Israele 11
TH - Thailandia 11
BG - Bulgaria 10
KZ - Kazakistan 10
DO - Repubblica Dominicana 9
LT - Lituania 9
OM - Oman 9
SV - El Salvador 9
BO - Bolivia 8
HN - Honduras 8
SC - Seychelles 8
TT - Trinidad e Tobago 8
ET - Etiopia 7
SY - Repubblica araba siriana 7
BH - Bahrain 6
DK - Danimarca 6
GT - Guatemala 6
KW - Kuwait 6
LB - Libano 6
SI - Slovenia 6
BY - Bielorussia 5
HU - Ungheria 5
KG - Kirghizistan 5
KH - Cambogia 5
LV - Lettonia 5
PR - Porto Rico 5
SK - Slovacchia (Repubblica Slovacca) 5
IR - Iran 4
LK - Sri Lanka 4
NI - Nicaragua 4
NO - Norvegia 4
PS - Palestinian Territory 4
CW - ???statistics.table.value.countryCode.CW??? 3
EU - Europa 3
GA - Gabon 3
GE - Georgia 3
Totale 57.874
Salva come PNG Salva come JPEG
Città #
Warsaw 6.076
Santa Clara 4.404
Ashburn 3.043
Fairfield 2.220
Singapore 2.184
Hong Kong 1.413
Woodbridge 1.066
Dublin 1.065
Seoul 999
Seattle 957
Chandler 947
Cambridge 866
Houston 863
Wilmington 756
Hefei 727
San Jose 694
Beijing 554
Milan 533
Council Bluffs 419
Ann Arbor 411
Altamura 404
Lawrence 396
Los Angeles 381
Ho Chi Minh City 369
Florence 326
Dallas 312
Buffalo 310
Princeton 295
Lauterbourg 277
The Dalles 271
Bern 270
Rome 258
Jacksonville 257
Hanoi 253
New York 248
Moscow 244
Helsinki 234
Boston 233
Munich 160
Melbourne 156
Mumbai 146
Boardman 134
Jakarta 120
San Diego 119
Kent 117
São Paulo 117
Bremen 114
Medford 105
Shanghai 105
Dong Ket 90
Tokyo 89
Clifton 86
London 86
Phoenix 83
Paris 77
Abidjan 72
Toronto 72
Turku 70
Orem 69
Frankfurt am Main 65
Naples 65
Bologna 62
Chicago 62
Atlanta 60
Montreal 58
Lappeenranta 56
Turin 56
Da Nang 55
Brooklyn 53
Redondo Beach 53
Chennai 46
Abuja 45
Figino 45
Waltham 45
Palermo 43
San Francisco 43
Denver 42
Barcelona 40
Hillsboro 40
Izmir 38
Belo Horizonte 35
Haiphong 35
Miano 34
Norwalk 34
Rio de Janeiro 34
Bengaluru 32
Curitiba 31
Falls Church 30
Biên Hòa 29
Tianjin 29
Vienna 29
Columbus 28
Dearborn 28
Johannesburg 28
Manchester 28
Venice 28
Amsterdam 27
Baghdad 27
Pune 27
Yubileyny 27
Totale 39.394
Salva come PNG Salva come JPEG
Nome #
Correlazioni tra genotipo e fenotipo nelle sindromi mieloproliferative croniche Ph-negative 474
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. 450
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 401
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 392
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. 390
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations 387
Essential Thrombocythemia 357
A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells 356
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. 349
Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms 349
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 347
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial 344
Validation of the Mayo alliance prognostic system for mastocytosis 344
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). 344
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 336
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 335
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 334
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation 333
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms 332
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives 331
EZH2 mutational status predicts poor survival in myelofibrosis. 328
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 326
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 323
Advances in understanding and management of myeloproliferative neoplasms 322
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. 321
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium 310
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. 309
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. 308
Thrombocytosis and leukocytosis interactions in vascular complications of essential thrombocythemia 307
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis 307
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. 306
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. 305
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. 302
Chronic myeloproliferative neoplasms: a collaborative approach. 300
Role of miR-34a-5p in hematopoietic progenitor cells proliferation and fate decision: Novel insights into the pathogenesis of primary myelofibrosis 297
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 287
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 287
Cardiovascular events and intensity of treatment in polycythemia vera. 286
Effect of mutation order on myeloproliferative neoplasms 285
Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus 281
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients 280
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. 278
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. 276
FLT3-mediated p38-MAPK activation participates in the control ofmegakaryopoiesis in primary myelofibrosis. 276
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. 275
Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells 272
Characterisation and discovery of novel miRNAs andmoRNAs in JAK2V617F mutated SET2 cells 271
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 271
Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms 269
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis 267
MPN Score 266
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis 264
Molecular mechanisms associated with leukaemic transformation of MPL-mutant myeloproliferative neoplasms. 264
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants 261
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis 250
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 250
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 249
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk ofsplanchnic vein thrombosis. 243
JAK2V617F-homozigosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant clone 237
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 232
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 230
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 230
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation 229
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 229
Overexpression of microRNA-16-2 contributes to the abnormalerythropoiesis in polycythemia vera. 228
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. 226
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 221
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. 218
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 218
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 218
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 211
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis 209
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis 209
Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis 207
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation 203
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. 202
THIRD GENERATION SEQUENCING OF NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA: IMPLICATIONS FOR PROGNOSIS 202
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients 202
A QUANTITATIVE ASSAY FOR JAK2V617F MUTATION IN MYELOPROLIFERATIVE DISORDERS BY ARMS-PCR AND CAPILLARY ELECTROPHORESIS 201
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 200
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 200
Inconsistencies in the association between the JAL2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases 199
A life-threatening ruxolitinib discontinuation syndrome 199
Mutations and prognosis in primary myelofibrosis. 198
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 197
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 197
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 195
CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles 193
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 192
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 192
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia 191
STAT1 activation in association with JAK2 exon 12 mutations 191
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients 190
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. 188
Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data 188
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 188
Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status 187
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 187
Treatment options for essential thrombocythemia and polycythemia vera 187
Insights into JAK2-V617F mutation in CML. 187
Totale 26.772
Salva come PNG Salva come JPEG
Categoria #
all - tutte 161.580
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 161.580
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.838 0 162 202 47 58 73 67 195 127 74 311 522
2022/20235.073 459 1.054 252 396 330 816 615 251 390 52 140 318
2023/20241.999 85 183 324 104 184 284 55 372 39 148 128 93
2024/202513.641 423 1.359 951 1.985 3.598 1.888 329 693 736 413 551 715
2025/202618.126 1.807 2.363 1.869 1.702 1.735 748 1.927 855 1.155 1.132 677 2.156
2026/20272.231 1.124 1.107 0 0 0 0 0 0 0 0 0 0
Totale 58.577